Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis.

Zouheir Ibrahim BitarAdnan Ma HajjiahOssama Sajeh MaadaraniMahmoud Mostafa ElzoueiryMohamed Refaat GoharMohamad AbdelfatahFawaz Alabdali

Published in: Nutrition and metabolic insights (2024)

Hypocalcemia induced by the denosumab treatment is more prevalent than previously shown in patients with osteoporosis receiving adequate calcium and vitamin D supplements. An elevated parathyroid hormone predicts hypocalcemia related to denosumab therapy in patients with normal calcium and vitamin D levels.

Keyphrases

bone mineral density
postmenopausal women
body composition
giant cell
combination therapy
mesenchymal stem cells
chemotherapy induced